$523.5 M

TGTX Mkt cap, 21-Oct-2019
TG Therapeutics Net income (Q2, 2019)36.2 M
TG Therapeutics EBIT (Q2, 2019)35.5 M
TG Therapeutics Cash, 30-Jun-201957.2 M
TG Therapeutics EV494.8 M

TG Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

152.4k152.4k152.4k152.4k

Revenue growth, %

R&D expense

13.7m40.1m47.7m69.2m

Operating expense total

13.7m40.1m47.7m69.2m118.9m174.6m

EBIT

(23.0m)(55.7m)(63.2m)(79.0m)(118.7m)(174.4m)

EBIT margin, %

(15071%)(36567%)(41462%)(51823%)

Interest expense

952.9k930.7k972.7k

Interest income

30.8k55.0k174.7k323.0k294.5k857.0k

Net Income

(20.5m)(55.8m)(62.9m)(78.3m)(118.5m)(173.5m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Operating expense total

17.1m13.9m14.0m16.1m27.7m28.5m31.6m40.6m44.4m34.4m34.7m35.6m

EBIT

(14.6m)(17.1m)(13.8m)(14.0m)(16.0m)(24.9m)(27.7m)(28.4m)(31.6m)(41.6m)(44.3m)(34.3m)(34.7m)35.5m

Interest expense

237.7k246.5k246.5k242.4k220.8k211.5k1.1m

Interest income

22.1k31.6k56.0k84.9k92.6k88.0k44.7k50.2k79.2k144.0k189.0k258.0k149.0k

Net Income

(14.6m)(17.1m)(13.7m)(13.8m)(15.9m)(24.8m)(27.7m)(28.4m)(31.5m)(41.5m)(44.1m)(34.0m)(35.2m)36.2m

TG Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

40.5m55.7m55.1m25.0m56.7m42.0m

Accounts Receivable

27.2k85.5k186.0k83.9k108.5k95.0k

Inventories

Current Assets

42.3m85.2m86.9m50.9m93.3m79.0m

PP&E

47.1k

Goodwill

799.4k799.4k799.4k799.4k799.4k799.0k

Total Assets

48.1m86.7m113.5m54.8m97.4m83.6m

Accounts Payable

4.8m4.0m9.3m15.3m25.9m36.4m

Short-term debt

677.8k211.5k68.9k127.6k67.0k

Current Liabilities

6.3m5.1m10.5m16.9m28.0m38.9m

Long-term debt

211.5k68.9k127.6k67.0k

Total Debt

677.8k423.1k137.8k255.2k134.0k

Total Liabilities

8.1m11.9m18.9m30.4m59.6m

Additional Paid-in Capital

79.7m175.5m259.9m272.4m422.0m552.5m

Retained Earnings

(95.2m)(158.1m)236.4m(354.9m)(528.3m)

Total Equity

40.1m80.1m101.6m35.9m67.0m24.0m

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.2 x1.1 x1.1 x1.5 x1.5 x3.5 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

50.2m49.6m37.1m53.2m86.0m60.3m65.5m36.5m28.6m29.2m95.6m77.6m91.8m82.9m105.7m70.7m64.3m57.2m

Accounts Receivable

11.1k74.7k53.8k89.7k190.3k158.5k164.1k133.8k108.5k22.8k43.3k79.0k87.0k80.0k

Current Assets

50.6m56.3m49.3m76.7m115.7m103.7m104.7m70.6m69.6m71.3m119.0m97.0m97.7m117.0m136.0m109.7m105.1m94.4m

PP&E

69.2k323.0k333.9k

Goodwill

799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.0k799.0k799.0k799.0k799.0k

Total Assets

54.3m58.2m56.3m77.5m117.3m123.6m127.4m100.1m94.8m75.7m123.3m101.2m101.8m121.0m140.7m114.4m117.5m106.6m

Accounts Payable

4.3m1.6m1.9m8.0m8.9m8.3m8.6m8.1m13.1m15.6m18.9m19.6m18.2m32.5m35.4m37.9m40.2m31.5m

Short-term debt

677.8k159.2k183.1k295.4k181.7k152.9k90.6k117.1k174.7k152.6k182.2k224.0k210.0k91.0k

Current Liabilities

5.7m2.0m2.6m8.9m9.6m9.2m9.7m8.9m14.1m16.9m19.7m20.8m19.8m33.3m36.9m40.2m60.9m56.0m

Long-term debt

295.4k181.7k152.9k90.6k117.1k174.7k152.6k182.2k224.0k210.0k91.0k28.3m28.5m

Total Debt

677.8k159.2k183.1k590.7k363.3k305.8k181.1k349.3k305.1k364.3k448.0k420.0k182.0k28.3m28.5m

Total Liabilities

9.7m3.7m4.2m10.5m10.7m11.1m10.6m16.1m22.2m23.2m22.2m35.8m39.3m42.6m98.3m93.4m

Additional Paid-in Capital

78.4m101.6m111.2m143.7m216.2m240.0m257.0m261.6m266.8m269.6m365.3m370.6m403.7m481.8m542.1m546.4m582.9m613.1m

Retained Earnings

(58.9m)(76.4m)(109.8m)(126.9m)(140.5m)(172.0m)(187.9m)(212.7m)(264.1m)(292.5m)(324.0m)(396.4m)(440.5m)(474.5m)(563.5m)599.7m

Total Equity

44.6m54.4m52.1m67.1m106.2m112.9m116.3m89.4m78.7m56.8m101.0m78.0m79.5m85.2m101.4m71.7m19.3m13.2m

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.2 x1.1 x1.1 x1.2 x1.1 x1.1 x1.1 x1.1 x1.2 x1.3 x1.2 x1.3 x1.3 x1.4 x1.4 x1.6 x6.1 x8.1 x

TG Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(20.5m)(55.8m)(62.9m)(78.3m)

Depreciation and Amortization

1.1k3.9k15.5k63.0k82.4k88.0k

Accounts Receivable

14.0k

Inventories

Accounts Payable

Cash From Operating Activities

(10.8m)(35.1m)(44.7m)(61.6m)(93.8m)(128.9m)

Purchases of PP&E

(42.2k)

Cash From Investing Activities

(4.9m)(18.4m)(24.7m)26.5m(8.2m)1.2m

Short-term Borrowings

(677.8k)

Cash From Financing Activities

39.8m68.6m68.7m5.0m133.7m113.6m

TG Therapeutics Ratios

USDY, 2019

EV/EBIT

13.9 x

EV/CFO

-7.1 x

Financial Leverage

8.1 x